Calypso Biotech - About the company
Calypso Biotech is an acquired company based in Plan les Ouates (Switzerland), founded in 2013. It operates as a Developer of antibody-based therapeutics for the treatment of gastrointestinal diseases. Calypso Biotech has raised $36.4M in funding from investors like Gilde Healthcare, Inkef and Fountain Healthcare Partners. The company has 3396 active competitors, including 1160 funded and 807 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.
Company Details
Developer of antibody-based therapeutics for the treatment of gastrointestinal diseases. The company's lead candidate drug is CALY-002 a monoclonal antibody inhibiting Interleukin-15 for treating celiac diseases, and dermatological diseases. Other candidates include CALY-001for auto-immune and inflammatory diseases.
- Website
- calypsobiotech.com
- Email ID
- *****@calypsobiotech.com
Key Metrics
Founded Year
2013
Location
Plan les Ouates, Switzerland
Stage
Acquired
Total Funding
$36.4M in 4 rounds
Latest Funding Round
Investors
Ranked
856th among 3396 active competitors
Employee Count
13 as on Jul 01, 2024
Exit Details
Acquired by Novartis (Jan 08, 2024)
Calypso Biotech's acquisition details
Click here to take a look at Calypso Biotech's acquisition in detail
Sign up to download Calypso Biotech's company profile
Calypso Biotech's funding and investors
Calypso Biotech has raised a total funding of $36.4M over 4 rounds. Its first funding round was on Mar 05, 2013. Its latest funding round was a Series A round on Sep 09, 2021 for $*****. 5 investors participated in its latest round. Calypso Biotech has 6 institutional investors.
Here is the list of recent funding rounds of Calypso Biotech:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 09, 2021 | 6235109 | Series A | 1445688 | 2094989 | 5027405 | 6306494 |
Feb 20, 2019 | 2439704 | Series A | 1651214 | 5650825 | 5373219 | |
Jul 01, 2016 | 5747812 | Grant (prize money) | 3520964 | 1137871 | 7814131 | 1214870 |
Access funding benchmarks and valuations. Sign up today!View details of Calypso Biotech's funding rounds and investors
Calypso Biotech's founders and board of directors
Founder? Claim ProfileCalypso Biotech's employee count trend
Calypso Biotech has 13 employees as of Jul 24. Here is Calypso Biotech's employee count trend over the years:
Uncover Calypso Biotech's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Calypso Biotech's Competitors and alternates
Top competitors of Calypso Biotech include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Calypso Biotech, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
3rd | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
856th | Calypso Biotech 2013, Plan les Ouates (Switzerland), Acquired | Developer of antibody-based therapeutics for the treatment of gastrointestinal diseases | $36.4M | 45/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Calypso Biotech's competitors? Click here to see the top ones
Calypso Biotech's Investments and acquisitions
Calypso Biotech has made no investments or acquisitions yet.
News related to Calypso Biotech
•
•
•
Novartis dances into JPM with $250M Calypso buyout, $185M RNAi allianceFierce Biotech•Jan 08, 2024•Novartis, Calypso Biotech, Merck, Merck
•
•
Clinical progression and €8M funding for Calypso BiotechStartupticker•Sep 20, 2021•Calypso Biotech, Fountain Healthcare Partners, Gilde Healthcare, Inkef Capital and 2 others
•
•
•
•
•
Calypso Biotech Licenses IBD Treatment to EA PharmaDrug Discovery & Development•Mar 31, 2017•EA Pharma, Calypso Biotech
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Calypso Biotech
Explore our recently published companies
- Shop Wafi - Jeddah based, 2015 founded, Deadpooled company
- Bixabotanical - Mumbai based, 2015 founded, Unfunded company
- Benhurconstruction - Unfunded company
- Saalfo Tech - Mysuru based, 2016 founded, Unfunded company
- Tolia - Thane based, 1979 founded, Unfunded company
- Uvtcpl - Mumbai based, 2023 founded, Unfunded company
